Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Merz Therapeutics will purchase substantially all of the assets of Acorda, including the rights to Inbrija (levodopa inhalation powder), Ampyra (dalfampridine), and Fampyra (dalfampridine). INBRIJA is used when needed for OFF episodes in adults with Parkinson's disease.
Lead Product(s): Etilevodopa
Therapeutic Area: Neurology Product Name: Inbrija
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Merz Pharma
Deal Size: $185.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition April 02, 2024
Details:
Under the termination, Acorda will regain global commercialization rights to Fampyra, a prolonged-release tablet formulation of the drug fampridine (4-aminopyridine, 4-AP or dalfampridine) for adult patients with multiple sclerosis with walking disability.
Lead Product(s): Fampridine
Therapeutic Area: Neurology Product Name: Fampyra
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Biogen
Deal Size: $510.0 million Upfront Cash: $110.0 million
Deal Type: Termination January 11, 2024
Details:
INBRIJA® (levodopa) is approved for intermittent treatment of OFF episodes in adults with Parkinson’s disease treated with carbidopa. INBRIJA utilizes ARCUS® pulmonary delivery system, a technology platform designed to deliver medication through inhalation.
Lead Product(s): Etilevodopa
Therapeutic Area: Neurology Product Name: Inbrija
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 06, 2023
Details:
The collaboration aims to provide INBRIJA® in China. Inbrija (levodopa) is indicated in the United States for the intermittent treatment of episodic motor fluctuations in adult patients with Parkinson's disease treated with a levodopa/dopa-decarboxylase inhibitor.
Lead Product(s): Etilevodopa
Therapeutic Area: Neurology Product Name: Inbrija
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Chance Pharmaceuticals
Deal Size: $144.0 million Upfront Cash: $2.5 million
Deal Type: Agreement May 08, 2023
Details:
Inbrija (levodopa) is levodopa/dopa-decarboxylase inhibitor, it is converted to dopamine replacement agent for the intermittent treatment of episodic motor fluctuations of Parkinson disease.
Lead Product(s): Etilevodopa
Therapeutic Area: Neurology Product Name: Inbrija
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Esteve Quimica
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 07, 2023
Details:
INBRIJA® (levodopa) is approved for intermittent treatment of OFF episodes in adults with Parkinson’s disease treated with carbidopa. INBRIJA utilizes ARCUS® pulmonary delivery system, a technology platform designed to deliver medication through inhalation.
Lead Product(s): Etilevodopa
Therapeutic Area: Neurology Product Name: Inbrija
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Catalent Pharma Solutions
Deal Size: $10.0 million Upfront Cash: Undisclosed
Deal Type: Agreement January 05, 2023
Details:
SYN117 (nepicastat), is a small molecule drug and the license agreement provides for its development for all non-psychiatric indications and therapeutic uses. The asset has been held by Acorda’s U.S. subsidiary, Biotie Therapies, Inc.
Lead Product(s): Nepicastat
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Asieris Pharmaceuticals
Deal Size: $7.5 million Upfront Cash: $0.5 million
Deal Type: Licensing Agreement August 29, 2022
Details:
INBRIJA® 33 mg (levodopa inhalation powder, hard capsules) is indicated in the EU for the intermittent treatment of episodic motor uctuations (OFF episodes) in adult patients with Parkinson’s disease treated with a levodopa/dopa-decarboxylase inhibitor.
Lead Product(s): Etilevodopa
Therapeutic Area: Neurology Product Name: Inbrija
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Esteve Huayi Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 16, 2022
Details:
Under the terms of the agreements, Acorda will receive a significant percentage of the selling price of INBRIJA in Latin America in exchange for supply of the product. Biopas plans on seeking marketing authorization in all countries to make Inbrija available for patients.
Lead Product(s): Etilevodopa
Therapeutic Area: Neurology Product Name: Inbrija
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Biopas Laboratories
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 11, 2022
Details:
Under the agreement, ESTEVE will have the exclusive distribution rights to INBRIJA in Germany and ACORDA will supply the product to ESTEVE. ESTEVE expects to launch INBRIJA in Germany by mid-2022.
Lead Product(s): Etilevodopa
Therapeutic Area: Neurology Product Name: Inbrija
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Esteve Huayi Pharmaceutical
Deal Size: Undisclosed Upfront Cash: $5.6 million
Deal Type: Agreement November 09, 2021